Results 151 to 160 of about 3,371,263 (384)

Severe Hyponatremia in the Emergency Department Incidence of Cerebral Edema and Risk of Osmotic Demyelination Syndrome

Academic Emergency Medicine, EarlyView.
ABSTRACT Study Objective Treatment strategies in severe hyponatremia aim at rapid sodium correction to prevent or treat cerebral edema but limit sodium rise to prevent osmotic demyelination syndrome (ODS). The true risk of edema or ODS in ED patients is unknown.
Volker Burst, Ramon Rabii, Julian Peto‐Madew, Thorsten Persigehl, Stefan Haneder, Matthias Johannes Hackl, Christoph Hüser, Moritz Trappe, Sadrija Cukoski, Kathrin Möllenhoff, Victor Suárez   +10 more
wiley   +1 more source

Impact of Early Antipsychotic Prescription Choice on Weight Gain in the First 5 Years of Psychotic Illness: a Retrospective Cohort Study

Neurology and Therapy
Introduction We analysed the effects of antipsychotic drug prescribing in year 1 of treatment for psychosis on future weight gain over 5 years. Methods We studied how weight changed over 5 years after the first diagnosis of psychosis/schizophrenia ...
Adrian Heald, George Tilston, John Julian Warner-Levy, Loren Wilkins, Richard Williams, Toby Pillinger, William Deakin, Damien Longson, Lamiece Hassan, Caroline Dalton, Gavin P. Reynolds, Joseph Firth   +11 more
doaj   +1 more source

Perospirone, a Novel Antipsychotic Agent, Hyperpolarizes Rat Dorsal Raphe Neurons via 5-HT1A Receptor

, 2003
Tsuguka Shiwa, Taku Amano, Hiroaki Matsubayashi, Takahiro Seki, Masashi Sasa, Norio Sakai   +5 more
openalex   +4 more sources

Neural Correlates of Cognitive Improvement After Virtual Reality‐Based Cognitive Remediation in Psychosis and Mood Disorders: A Randomized Controlled Trial

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Cognitive impairment in mood disorders and schizophrenia spectrum disorders hampers patients' clinical and functional outcomes. A key challenge in pro‐cognitive treatment development is the limited insight into the underlying neurocircuitry correlates of cognitive changes.
Viktoria Damgaard, Andreas Elleby Jespersen, Ida Kruse Søndergaard, Anders Lumbye, Maj Vinberg, Louise Birkedal Glenthøj, Merete Nordentoft, Anjali Sankar, Gitte Moos Knudsen, Julian Macoveanu, Kamilla Woznica Miskowiak   +10 more
wiley   +1 more source

Safety and tolerability of antipsychotics: focus on amisulpride

Drug, Healthcare and Patient Safety, 2010
Mario F Juruena1, Eduardo Pondé de Sena2, Irismar Reis de Oliveira31Stress and Affective Disorders Programme, Department of Neuroscience and Behaviour, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil ...
Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira   +2 more
doaj  

Cognitive and Psychomotor Processing Speed in Medication‐Naïve Individuals With First‐Episode of Psychosis: The Role of Peripheral Inflammatory Markers

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background and Hypothesis Deficits in processing speed (PS) and psychomotor speed (PMS) are core cognitive impairments in schizophrenia spectrum disorders, including first‐episode psychosis (FEP). Neuroinflammation has been proposed as a potential contributor to these deficits.
Ángel Yorca‐Ruiz, Carlos Martínez Asensi, Rebeca Magdaleno Herrero, Alexandre Díaz‐Pons, Víctor Ortiz‐García de la Foz, Luis Manuel Fernández Cacho, Ana Catalán Alcantara, Benedicto Crespo‐Facorro, Rosa Ayesa‐Arriola   +8 more
wiley   +1 more source

Associations Between Cognitive Functions and Subsequent Mood Disorder Prognosis in Low‐Risk, High‐Risk and Affected Monozygotic Twins: A Seven‐Year Follow‐Up Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Aberrant cognition is common among individuals at familial risk for mood disorders (MD) and those already affected. However, long‐term prospective studies are needed to determine whether specific cognitive features predict illness onset and relapse; and whether cognitive impairments reflect neurodevelopmental traits or ...
Kamilla Miskowiak, Hanne Lie Kjærstad, Stella Lystlund, Anjali Sankar, Lars Kessing, Maj Vinberg   +5 more
wiley   +1 more source

Influence of Sex and Diagnosis on Clinical Variables and Neurocognitive Performance in Severe Mental Illness. Results From the PsyCourse Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Bipolar disorder (BD) and schizophrenia (SZ) are serious mental illnesses (SMI) with overlapping symptoms but distinct differences in onset and course. Sex differences are an area of growing interest in SMI. This study aims to examine potential interactions between sex and diagnosis across a broad range of variables, to compare ...
Maria Serra‐Navarro, Maria Heilbronner, Brisa Solé, Roger Borràs, Anabel Martinez‐Arán, Kristina Adorjan, Alba Navarro‐Flores, Mojtaba Oraki Kohshour, Daniela Reich‐Erkelenz, Eva C. Schulte, Fanny Senner, Ion‐George Anghelescu, Volker Arolt, Bernhard T. Baune, Udo Dannlowski, Detlef E. Dietrich, Andreas J. Fallgatter, Christian Figge, Markus Jäger, Georg Juckel, Carsten Konrad, Jens Reimer, Eva Z. Reininghaus, Max Schmauß, Andrea Schmitt, Carsten Spitzer, Jens Wiltfang, Jörg Zimmermann, Sergi Papiol, Urs Heilbronner, Peter Falkai, Thomas G. Schulze, Eduard Vieta, Carla Torrent, Monika Budde, Silvia Amoretti   +35 more
wiley   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson’s Disease and Comorbid Depression

Drug, Healthcare and Patient Safety, 2020
Farid Chekani,1 Holly M Holmes,2 Michael L Johnson,1 Hua Chen,1 Jeffrey T Sherer,1 Rajender R Aparasu1 1Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX 77204-5047, USA; 2Division of ...
Chekani F, Holmes HM, Johnson ML, Chen H, Sherer JT, Aparasu RR   +5 more
doaj